Effect of Yukgunja-tang for Anorexia in Cancer Patients : A Randomized Controlled Trial

Dunsan Korean Medicine Hospital of Daejeon University0 个研究点目标入组 52 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•1) patients who have a histologically or cytologically confirmed solid tumour; individuals who are suffering from anorexia
•2) men and women aged 20-80 years who can write and understand
•3) Visual analog scale(VAS) for anorexia = 40/100 mm
•5) neutrophils =1500/µL, platelets =100,000/µL
•6) total bilirubin of the maximum normal level or less (1.2 mg/dL)
•7) alanine aminotransferase(ALT), aspartate aminotransferase(AST) lower than 2-fold the upper limit of normal (35/45U/l)
•8) creatinine lower than 1.5 fold the upper limit of normal (1.09 mg/dL)
•9) written informed consent for participation in the trial

•1) impossible to intake orally
•2) Patients who are undergoing chemotherapy or less than one month after completion of chemotherapy
•3) survived at least 5 years after cancer diagnosis (with no additional cancer diagnosis)
•4) Eastern Cooperative Oncology Group (ECOG) performance status score = 3
•5) Patients who have dementia, delirium or depression
•6) reports more than 7 points of Numeric Pain Rating Scale in 2 weeks of screening
•7) Patients who have diseases like hypoadrenalism which can influence on appetite
•8) Patients who are taking appetite stimulants such as megestrol acetate, corticosteroids and thalidomide
•9) Women of childbearing potential
•10) others who are judged not to be appropriate to study

发起方

Dunsan Korean Medicine Hospital of Daejeon University